Clearside Biomedical Inc
NASDAQ:CLSD
Clearside Biomedical Inc
NASDAQ:CLSD
Price:
1.32 USD
3.94%
Market Closed
Updated:
May 4, 2024
Clearside Biomedical Inc
Net Income (Common)
|
Clearside Biomedical Inc
Net Income (Common) Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
Net Income (Common)
-$32.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$40.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$2.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Clearside Biomedical Inc's Net Income (Common)?
Net Income (Common)
-32.5m
USD
-32.5m
USD
Based on the financial report for Dec 31, 2023, Clearside Biomedical Inc's Net Income (Common) amounts to -32.5m USD.
What is Clearside Biomedical Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
17%
17%
Over the last year, the Net Income (Common) growth was 1%. The average annual Net Income (Common) growth rates for Clearside Biomedical Inc have been -21% over the past three years , 17% over the past five years .
You don't have any saved screeners yet
